Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.
Identifieur interne : 000830 ( Main/Exploration ); précédent : 000829; suivant : 000831Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.
Auteurs : RBID : pubmed:23486323English descriptors
- KwdEn :
- Adult, Aged, Female, Fluorodeoxyglucose F18 (diagnostic use), Humans, Male, Middle Aged, Multimodal Imaging, Neoplasms, Glandular and Epithelial (radionuclide imaging), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Positron-Emission Tomography, ROC Curve, Retrospective Studies, Thymus Neoplasms (radionuclide imaging), Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed.
- MESH :
- chemical , analogs & derivatives : Octreotide.
- chemical , diagnostic use : Fluorodeoxyglucose F18, Octreotide.
- radionuclide imaging : Neoplasms, Glandular and Epithelial, Thymus Neoplasms.
- Adult, Aged, Female, Humans, Male, Middle Aged, Multimodal Imaging, Positron-Emission Tomography, ROC Curve, Retrospective Studies, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed.
Abstract
This study aimed to test the role of combined imaging with 18F-FDG-PET/CT and 111In-octreotide SPECT in characterizing thymic epithelial tumors (TETs).
DOI: 10.1097/RLU.0b013e318286bd84
PubMed: 23486323
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.</title><author><name sortKey="De Luca, Serena" uniqKey="De Luca S">Serena De Luca</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomorphological and Functional Sciences, University of Naples Federico II, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomorphological and Functional Sciences, University of Naples Federico II, Naples</wicri:regionArea></affiliation></author><author><name sortKey="Fonti, Rosa" uniqKey="Fonti R">Rosa Fonti</name></author><author><name sortKey="Palmieri, Giovannella" uniqKey="Palmieri G">Giovannella Palmieri</name></author><author><name sortKey="Federico, Piera" uniqKey="Federico P">Piera Federico</name></author><author><name sortKey="Del Prete, Giuseppina" uniqKey="Del Prete G">Giuseppina Del Prete</name></author><author><name sortKey="Pacelli, Roberto" uniqKey="Pacelli R">Roberto Pacelli</name></author><author><name sortKey="Pace, Leonardo" uniqKey="Pace L">Leonardo Pace</name></author><author><name sortKey="De Placido, Sabino" uniqKey="De Placido S">Sabino De Placido</name></author><author><name sortKey="Salvatore, Marco" uniqKey="Salvatore M">Marco Salvatore</name></author><author><name sortKey="Del Vecchio, Silvana" uniqKey="Del Vecchio S">Silvana Del Vecchio</name></author></titleStmt><publicationStmt><date when="2013">2013</date><idno type="doi">10.1097/RLU.0b013e318286bd84</idno><idno type="RBID">pubmed:23486323</idno><idno type="pmid">23486323</idno><idno type="wicri:Area/Main/Corpus">000745</idno><idno type="wicri:Area/Main/Curation">000745</idno><idno type="wicri:Area/Main/Exploration">000830</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multimodal Imaging</term><term>Neoplasms, Glandular and Epithelial (radionuclide imaging)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Positron-Emission Tomography</term><term>ROC Curve</term><term>Retrospective Studies</term><term>Thymus Neoplasms (radionuclide imaging)</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Neoplasms, Glandular and Epithelial</term><term>Thymus Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multimodal Imaging</term><term>Positron-Emission Tomography</term><term>ROC Curve</term><term>Retrospective Studies</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study aimed to test the role of combined imaging with 18F-FDG-PET/CT and 111In-octreotide SPECT in characterizing thymic epithelial tumors (TETs).</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23486323</PMID><DateCreated><Year>2013</Year><Month>04</Month><Day>08</Day></DateCreated><DateCompleted><Year>2013</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-0229</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical nuclear medicine</Title><ISOAbbreviation>Clin Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.</ArticleTitle><Pagination><MedlinePgn>354-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0b013e318286bd84</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to test the role of combined imaging with 18F-FDG-PET/CT and 111In-octreotide SPECT in characterizing thymic epithelial tumors (TETs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated 20 patients with newly diagnosed TETs who had undergone concomitant 18F-FDG-PET/CT and 111In-octreotide SPECT. Thymic epithelial tumors were classified by World Health Organization (WHO) as low-risk thymomas (5), high-risk thymomas (4), and thymic carcinomas (11, among which 6 neuroendocrine tumors). Patients were staged according to Masaoka system. 18F-FDG-PET/CT was performed and SUV(max) of primary tumors was recorded. 111In-octreotide SPECT of the thorax was performed, and tumor-to-background ratio was determined on the 24-hour coronal sections.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients showed increased 18F-FDG uptake in mediastinal lesions. SUV(max) were significantly correlated with WHO classification (r = 0.66, P < 0.01) and with Masaoka stage (r = 0.60, P < 0.01). SUV(max) of low-risk thymomas (mean [SD], 2.87 [0.83]) were significantly lower than those of high-risk thymomas (mean [SD], 7.21 [1.73], P < 0.01) and of thymic carcinomas (mean [SD], 9.39 [5.80], P < 0.05), whereas no significant difference was found between high-risk thymomas and thymic carcinomas. SUV(max) of all high-risk thymomas and thymic carcinomas was 4.5 or greater. All primary tumors were detected by In-octreotide SPECT, and tumor-to-background ratios ranged between 1.67 and 10.10. No statistically significant correlation was found between tumor-to-background ratios and WHO classification (r = 0.24, P = 0.36) and Masaoka stages (r = 0.31, P = 0.23). However tumor-to-background ratios of thymic neuroendocrine tumors (mean [SD], 5.71 [3.09]) were significantly higher than those of all other TETs with SUV(max) of 4.5 or greater (mean [SD], 2.41 [0.56]; P < 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">18F-FDG-PET/CT scan allows to differentiate high-risk epithelial tumors and thymic carcinomas from low-risk thymomas, whereas 111In-octreotide SPECT may identify neuroendocrine tumors among those showing high 18F-FDG uptake.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>Serena</ForeName><Initials>S</Initials><Affiliation>Department of Biomorphological and Functional Sciences, University of Naples Federico II, Naples, Italy.</Affiliation></Author><Author ValidYN="Y"><LastName>Fonti</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Palmieri</LastName><ForeName>Giovannella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Federico</LastName><ForeName>Piera</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Del Prete</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pacelli</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pace</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>De Placido</LastName><ForeName>Sabino</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Del Vecchio</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Nucl Med</MedlineTA><NlmUniqueID>7611109</NlmUniqueID><ISSNLinking>0363-9762</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance>Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease">Thymic epithelial tumor</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Multimodal Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thymus Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0b013e318286bd84</ArticleId><ArticleId IdType="pubmed">23486323</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000830 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000830 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23486323
|texte= Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23486323" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |